Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Leukemia, Myeloid, Acute 190Leukemia, Lymphocytic, Chronic, B-Cell 69Myelodysplastic Syndromes 48Recurrence 30Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Mantle-Cell 21Leukemia, Myelomonocytic, Chronic 20Leukemia, Biphenotypic, Acute 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Hematologic Neoplasms 14Lymphoma, Non-Hodgkin 13Lymphoma 13Burkitt Lymphoma 13Lymphoma, B-Cell, Marginal Zone 12Multiple Myeloma 11Lymphoma, Large B-Cell, Diffuse 11Neoplasms 10Waldenstrom Macroglobulinemia 8Myeloproliferative Disorders 8Lymphoma, Follicular 8Lymphoma, B-Cell 7Neoplasm, Residual 6Leukemia, Myeloid 5Blastic Plasmacytoid Dendritic Cell Neoplasm 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4GATA2 Deficiency 4Leukemia, Monocytic, Acute 3Leukemia, B-Cell 3

Interventions

Dexamethasone 13daratumumab 7Bortezomib 7Cyclophosphamide 6Calcium Dobesilate 5ixazomib 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4venetoclax 3belantamab mafodotin 3Specimen Handling 34-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 3pomalidomide 2isatuximab 2X-Rays 2Polymerase Chain Reaction 2Phantoms, Imaging 2Magnetic Resonance Spectroscopy 2Clinical Protocols 2Biopsy 2siltuximab 1Valganciclovir 1Tissue Banks 1Therapeutics 1Stem Cell Transplantation 1Spectrometry, Fluorescence 1Positron-Emission Tomography 1Pharmaceutical Preparations 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × venetoclax × 1 year × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06192979 2026-03-09

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Peking University People's Hospital

Phase NA Recruiting
41 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡